Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure.

Abstract:

BACKGROUND:Several studies have previously demonstrated the survival benefit of both EGFR-TKI treatment and chemotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after failure of EGFR-TKI therapy, focusing on the number of organs with metastasis (hereafter, metastatic organs). METHODS:Between January 2010 and December 2016, consecutive patients with EGFR-mutated NSCLC who were started on first-line EGFR-TKI were reviewed. The factors influencing withholding systemic chemotherapy and the post-progression survival (PPS) after failure of EGFR-TKI were investigated. RESULTS:A total of 393 patients were started on first-line EGFR-TKI during the study period. After excluding patients maintained on EGFR-TKI or who received osimertinib targeting secondary EGFR T790M, 297 patients were included in the analysis. Among these, 180 (60.6%) received chemotherapy after failure of EGFR-TKI (TKI-Ct group), while the remaining 117 (39.4%) received no chemotherapy (TKI-only group). Multivariate analysis identified older age (≥75 years: odds ratio [OR] = 0.25, 95% confidence interval [CI]: 0.11-0.43, P < 0.001), poor performance status (PS) (≥2: OR = 0.06, 95% CI: 0.03-0.15, P < 0.001), and three or more metastatic organs (OR = 0.42, 95% CI: 0.22-0.80, P = 0.008) as being significantly associated with withholding of chemotherapy after failure of EGFR-TKI. CONCLUSION:A relatively large number of metastatic organs and a poor PS were associated with the withholding of subsequent chemotherapy after failure of EGFR-TKI in EGFR-mutated NSCLC patients. Further research for patients with such a poor prognosis should be investigated in the future.

journal_name

Thorac Cancer

journal_title

Thoracic cancer

authors

Mizuno T,Horinouchi H,Watanabe S,Sato J,Morita R,Murakami S,Goto Y,Kanda S,Fujiwara Y,Yamamoto N,Ohe Y

doi

10.1111/1759-7714.13360

subject

Has Abstract

pub_date

2020-04-01 00:00:00

pages

1038-1044

issue

4

eissn

1759-7706

issn

1759-7714

journal_volume

11

pub_type

杂志文章
  • Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer.

    abstract::Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first-line treatment option for extensive-stage small cell lung cancer (ES-SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first-line chemotherapy are limited,...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13588

    authors: Kataoka N,Kunimatsu Y,Tachibana Y,Sugimoto T,Sato I,Tani N,Ogura Y,Hirose K,Takeda T

    更新日期:2020-09-01 00:00:00

  • MicroRNA-153-3p regulates cell proliferation and cisplatin resistance via Nrf-2 in esophageal squamous cell carcinoma.

    abstract:BACKGROUND:Our recent studies have indicated that miR-153-3p is downregulated in the esophageal squamous cell carcinoma (ESCC) cell lines and tissues. Upregulation of miR-153-3p was found to inhibit migration and invasion of ESCC cells. However, whether miR-153-3p regulates the cisplatin sensitivity in ESCC cells remai...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13326

    authors: Zuo J,Zhao M,Fan Z,Liu B,Wang Y,Li Y,Lv P,Xing L,Zhang X,Shen H

    更新日期:2020-03-01 00:00:00

  • Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.

    abstract:BACKGROUND:Tumor mutation burden (TMB) is an important determinant and biomarker for response of targeted therapy and prognosis in patients with lung cancer. The present study aimed to determine whether radiomics signature could non-invasively predict the TMB status and driver mutations in patients with resectable earl...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13163

    authors: Wang X,Kong C,Xu W,Yang S,Shi D,Zhang J,Du M,Wang S,Bai Y,Zhang T,Chen Z,Ma Z,Wang J,Dong G,Sun M,Yin R,Chen F

    更新日期:2019-10-01 00:00:00

  • Sebaceous-like clear cell changes in primary lung cancer.

    abstract::We examined two cases of primary lung cancer with sebaceous-like clear cells (SLCCs), defined as clear carcinoma cells with microvacuolated cytoplasm and centrally located nuclei, which were selected from among 281 surgical/autopsy cases of lung cancer (2/281, 0.7%). Both cases were higher stage (stage IIA and IIIA), ...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12004

    authors: Matsukuma S,Obara K,Kono T,Takeo H,Sato K

    更新日期:2013-11-01 00:00:00

  • Female breast cancer incidence and mortality in China, 2013.

    abstract:BACKGROUND:Breast cancer is the most common cancer among women. Population-based cancer registration data from the National Central Cancer Registry were used to analyze and evaluate the incidence and mortality rates in China in 2013, providing scientific information for cancer prevention and control. METHODS:Pooled da...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12426

    authors: Zuo TT,Zheng RS,Zeng HM,Zhang SW,Chen WQ

    更新日期:2017-05-01 00:00:00

  • Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer.

    abstract:BACKGROUND:In cases of EGFR-tyrosine kinase inhibitor (TKI) failure, re-biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re-biopsy is challenging because of several hurdles. We assessed the feasibility of re-biopsy in advanced non-small cell lung cancer...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12762

    authors: Kim TO,Oh IJ,Kho BG,Park HY,Chang JS,Park CK,Shin HJ,Lim JH,Kwon YS,Kim YI,Lim SC,Kim YC,Choi YD

    更新日期:2018-07-01 00:00:00

  • Pharmacokinetic analysis of gefitinib in a patient with advanced non-small cell lung cancer undergoing hemodialysis.

    abstract::Patients undergoing hemodialysis (HD) are frequently elderly with poor performance status and usually cannot withstand chemotherapy because of its toxicities. We report a case of an elderly woman with chronic renal failure undergoing HD who was diagnosed with advanced non-small cell lung cancer and treated with orally...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12263

    authors: Luo J,Ni L,Wang M,Zhong W,Xiao Y,Zheng K,Hu P

    更新日期:2016-03-01 00:00:00

  • Micro ribonucleic acid-93 promotes proliferation and migration of esophageal squamous cell carcinoma by targeting disabled 2.

    abstract:BACKGROUND:Accumulated evidence has revealed that the dysregulation of micro ribonucleic acids (miRNAs) may contribute to esophageal squamous cell carcinoma (ESCC). MiR-93, which is a member of the miRNA cluster miR-106b∼25, has been widely studied for its tumor promoting effect on different types of cancers. However, ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12242

    authors: Li C,Ding C,Chen T,Chen J,Xu Z,Lei Z,Xu C,Zhao J

    更新日期:2015-07-01 00:00:00

  • Efficacy of repeated surgery is superior to that of non-surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer.

    abstract:BACKGROUND:The current study aimed to determine the oncological efficacy and surgical safety of multiple pulmonary resections (MPRs) after prior curative surgery for local regional recurrent or second primary lung cancers. METHODS:All cases of lung cancer included in our prospective database between January 2000 and J...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12790

    authors: Zhou H,Kang X,Dai L,Yan W,Yang Y,Lin Y,Chen KN

    更新日期:2018-08-01 00:00:00

  • Bronchoscopic debulking for endobronchial malignancy: Predictors of recanalization and recurrence.

    abstract:BACKGROUND:Central airway obstruction related to endobronchial malignancy is one of the most difficult oncological complications and requires efficient palliative intervention. METHODS:Fifty-three consecutive patients with unresectable endobronchial malignancy receiving bronchoscopic cryotherapy as palliative treatmen...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12248

    authors: Kuo SC,Lo YL,Chou CL,Chung FT,Lin SM,Liu CY,Kuo HP

    更新日期:2015-11-01 00:00:00

  • Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts.

    abstract:BACKGROUND:The combination of EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy is thought to increase treatment efficacy in non-small-cell lung cancer (NSCLC). This study investigated the efficacy and potential mechanisms of different combined modes of icotinib plus pemetrexed in EGFR-mutant lung adenocarcinoma ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12818

    authors: Cui J,Zhang Y,Su D,Li T,Li Y

    更新日期:2018-09-01 00:00:00

  • Esophagogastric reconstruction using remnant stomach with a single vessel pedicel: Technique and outcomes.

    abstract::Esophageal cancer with a history of distal gastrectomy is a clinical problem. To our knowledge there have been no reports of remnant stomach fed from the left gastroepiploic artery being used in esophageal reconstruction. We, herein, report four cases of esophagogastric reconstruction using remnant stomach with a sing...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12054

    authors: You B,Hou SC,Li H,Hu B

    更新日期:2014-03-01 00:00:00

  • Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.

    abstract:BACKGROUND:Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). While rapid progression (RP) has been proposed as a non-negligible pattern of response to ICIs, its definition and related factors remain unclear. This study aimed to develop a clinical definition of ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13370

    authors: Zhang L,Bai L,Liu X,Liu Y,Li S,Liu J,Zhang S,Yang C,Ren X,Cheng Y

    更新日期:2020-05-01 00:00:00

  • Uniportal video-assisted thoracoscopic left pneumonectomy: Retrospective analysis of eighteen consecutive patients from a single center.

    abstract:BACKGROUND:Uniportal video-assisted thoracoscopic surgery (VATS) is being more widely used in lung cancer, yet reports on its application in pneumonectomies are limited. This study aimed to evaluate the safety and feasibility of uniportal video-assisted thoracoscopic left pneumonectomy for lung cancer. METHODS:A serie...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13728

    authors: Li J,Xue Q,Gao Y,Mao Y,Zhao J,Gao S

    更新日期:2021-01-06 00:00:00

  • Characteristics of the local recurrence pattern after curative resection and values in target region delineation in postoperative radiotherapy for lower thoracic esophageal squamous cell cancer.

    abstract:BACKGROUND:The aim of this study was to investigate the patterns and influencing factors of local-regional recurrence of lower thoracic esophageal squamous cell carcinoma (TESCC) after curative resection and to delineate the clinical target volume (CTV) of postoperative radiotherapy (PORT). METHODS:From January 2009 t...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12499

    authors: Liu J,Cai X,Liu Q,Li H,Cheng Y,Fu X

    更新日期:2017-11-01 00:00:00

  • Lymph node metastasis in Chinese patients with clinical T1 non-small cell lung cancer: A multicenter real-world observational study.

    abstract:BACKGROUND:Approximately 8.3-15.9% of patients with clinical stage I non-small cell lung cancer are subsequently shown to have lymph node metastasis. However, the clinical characteristics of patients with lymph node metastasis in China are not fully understood. METHODS:This is a multicenter retrospective analysis of p...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12970

    authors: Chen B,Wang X,Yu X,Xia WJ,Zhao H,Li XF,Liu LX,Liu Y,Hu J,Fu XN,Li Y,Xu YJ,Liu DR,Yang HY,Xu L,Jiang F

    更新日期:2019-03-01 00:00:00

  • Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective study.

    abstract:BACKGROUND:  The optimal strategy was not established for patients who initially responded to gefitinib although re-administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been proven to be an option. Gefitinib and erlotinib were compared as salvage treatment after gefitinib fail...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/j.1759-7714.2012.00152.x

    authors: Yu S,Wang Y,Li J,Hao X,Wang B,Wang Z,Zhang X,Shi Y

    更新日期:2013-05-01 00:00:00

  • Survival in early lung cancer patients treated with high dose radiotherapy is independent of pathological confirmation.

    abstract:BACKGROUND:Approximately 15% of lung cancer patients are diagnosed in early stages. Microscopic proof of disease cannot always be obtained because of comorbidity or reluctance to undergo invasive diagnostic procedures. In the current study, survival data of patients with and without pathology are compared. METHODS:One...

    journal_title:Thoracic cancer

    pub_type: 临床试验,杂志文章

    doi:10.1111/1759-7714.12966

    authors: Zehentmayr F,Sprenger M,Rettenbacher L,Wass R,Porsch P,Fastner G,Pirich C,Studnicka M,Sedlmayer F

    更新日期:2019-02-01 00:00:00

  • CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.

    abstract::ROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated re...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12617

    authors: Zhu YC,Zhou YF,Wang WX,Xu CW,Zhuang W,Du KQ,Chen G

    更新日期:2018-05-01 00:00:00

  • Safety of endobronchial ultrasound-guided transbronchial needle aspiration in patients with lung cancer within a year after percutaneous coronary intervention.

    abstract:BACKGROUND:Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS-TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (PCI) has not been de...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12846

    authors: Gil HI,Choe J,Jeong BH,Um SW,Jeon K,Hahn JY,Kim H,Kwon OJ,Chang YS,Lee K

    更新日期:2018-11-01 00:00:00

  • Brain cavernous hemangioma mimicking radiation-induced necrosis in a patient with non-small cell lung cancer.

    abstract::In patients with non-small cell lung cancer (NSCLC), stereotactic radiotherapy (SRT) is one of the standard therapies for those suffering with intracranial metastatic NSCLC. Radiation-induced necrosis (RIN) sometimes occurs as the result of the delayed effects of SRT. The magnetic resonance imaging (MRI) of RIN typica...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13494

    authors: Takamori S,Seto T,Jinnouchi M,Matsubara T,Haratake N,Miura N,Toyozawa R,Yamaguchi M,Takenoyama M

    更新日期:2020-07-01 00:00:00

  • Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.

    abstract:BACKGROUND:Many randomized clinical trials have demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy, either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Howev...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12275

    authors: Sun H,Sun X,Zhai X,Guo J,Liu Y,Ying J,Wang Z

    更新日期:2016-01-01 00:00:00

  • Surgical resection versus stereotactic body radiation therapy in early stage bronchopulmonary large cell neuroendocrine carcinoma.

    abstract:BACKGROUND:Surgery is the standard of care for early stage non-small cell lung cancer (NSCLC). Stereotactic body radiotherapy (SBRT) is another definitive treatment option for those patients who have not been treated surgically. Comparison of approaches is being explored in NSCLC, but has yet to be compared exclusively...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13260

    authors: Lo H,Abel S,Finley G,Weksler B,Colonias A,Wegner RE

    更新日期:2020-02-01 00:00:00

  • Serum exosomal miR-1269a serves as a diagnostic marker and plays an oncogenic role in non-small cell lung cancer.

    abstract:BACKGROUND:Early diagnosis improves the prognosis for non-small cell lung cancer (NSCLC); therefore, there is a pressing need for effective diagnostic methods for NSCLC. Increasing evidence indicates that serum exosomal micro RNAs (miRNAs) represent promising diagnostic and prognostic markers for multiple cancers. Here...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13644

    authors: Wang X,Jiang X,Li J,Wang J,Binang H,Shi S,Duan W,Zhao Y,Zhang Y

    更新日期:2020-12-01 00:00:00

  • Trends in incidence and mortality of esophageal cancer in Inner Mongolia, 2010-2015.

    abstract:BACKGROUND:Esophageal cancer is among the leading cancer types in Inner Mongolia. This study aimed to investigate the incidence and mortality rates of esophageal cancer in 2015 and the trends in these rates in the 2010-2015 period in this region. METHODS:National Colorectal Cancer Roundtable (NCCR) screening methods a...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13552

    authors: Xi Y,Dong W,Qiao L,Han K,Chen W,Wang W

    更新日期:2020-09-01 00:00:00

  • Scutellarin suppresses proliferation and promotes apoptosis in A549 lung adenocarcinoma cells via AKT/mTOR/4EBP1 and STAT3 pathways.

    abstract:BACKGROUND:Scutellarin (SCU), a flavonoid isolated from Erigeron breviscapus (Vant.) Hand.-Mazz., increases autophagy and apoptosis in the adenocarcinoma A549 cell line, which is resistant to cisplatin. However, whether SCU alone has antitumor activity against non-small cell lung cancer (NSCLC) is unknown. METHODS:Cel...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12962

    authors: Cao P,Liu B,Du F,Li D,Wang Y,Yan X,Li X,Li Y

    更新日期:2019-03-01 00:00:00

  • Predictors of survival in patients who underwent video-assisted thoracic surgery talc pleurodesis for malignant pleural effusion.

    abstract:BACKGROUND:Patients with malignant pleural effusion have a limited life expectancy. An increase in pleural and oncological treatment options and more accurate prognostic evaluation may help individualize treatment strategies. The aim of this study was to identify the prognostic indicators of overall survival (OS) after...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12354

    authors: Yoon DW,Cho JH,Choi YS,Kim J,Kim HK,Zo JI,Shim YM

    更新日期:2016-07-01 00:00:00

  • Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients.

    abstract:BACKGROUND:Most non-small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK-TKI therapies; however, little clinical data exists on the clinical ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13143

    authors: Haratake N,Seto T,Takamori S,Toyozawa R,Nosaki K,Miura N,Ohba T,Toyokawa G,Taguchi K,Yamaguchi M,Shimokawa M,Takenoyama M

    更新日期:2019-09-01 00:00:00

  • Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database.

    abstract:BACKGROUND:Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor that originates from the pleura and has a poor prognosis. Eligible patients can benefit from surgery, but their survival is affected by many factors. Therefore, we created a graphic model that could predict the prognosis of surgically treate...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13063

    authors: Zhuo M,Zheng Q,Chi Y,Jia B,Zhao J,Wu M,An T,Wang Y,Li J,Zhao X,Yang X,Zhong J,Chen H,Dong Z,Wang J,Zhai X,Wang Z

    更新日期:2019-05-01 00:00:00

  • Basic fibroblast growth factor shows prognostic impact on survival in operable non-small cell lung cancer patients.

    abstract:BACKGROUND:The important role of angiogenesis displaying in tumor development and metastasis has been generally realized. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and endostatin (ES) are critical members of angiogenesis modulating the balance between pro-angiogenenic and anti-ang...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12202

    authors: Hu MM,Hu Y,Gao GK,Han Y,Shi GL,Li BL

    更新日期:2015-07-01 00:00:00